As tech companies seize space South of Market, their employees move into the Mission and grassroots groups protest against rising rents and tech shuttle buses, the parallel biotech boom has largely escaped popular wrath.
After all, no one’s is stepping in front of a Genentech bus in Cole Valley.
But biotech’s three-year parade of IPOs and venture funding announcements is starting to get some attention. Gilead Sciences Inc. (NASDAQ: GILD), for example, has come under fire for the initial $1,000-a-pill pricing of its groundbreaking hepatitis C drugs Sovaldi and Harvoni. And Illumina Inc. (NASDAQ: ILMN) and the developer of a 20-acre Foster City site, where it wants to consolidate much of its Bay Area operations, is getting pressure from city council members to mitigate traffic congestion and help pay for school programs.
Hey, check out all the research scientist jobs. Post your resume today!
